A β-carboline derivative and its preparation method, pharmaceutical composition and application

Through the structural transformation and synthesis of the β-carbolin derivative JYJ-21, a series of β-carbolin derivatives were designed to solve the problem of poor efficacy of existing liver cancer treatment drugs and achieve effective treatment for liver cancer cells Inhibition and compound preparation efficiency improve, providing the potential of new anti-hepatocellular drugs.

CN116535403BActive Publication Date: 2024-12-03SHENYANG PHARMA UNIV
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202310509005.6
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Filing Date
2023-05-06
Publication Date
2024-12-03
Estimated Expiration
2043-05-06

AI Technical Summary

Technical Problem

The number of targeted drugs for the treatment of liver cancer is limited and the effect is not ideal. In particular, the therapeutic effect of sorafenib can only extend the patient's survival time by 2.8 months, and there is a lack of anti-hepatic cancer drugs with a new mechanism of action and structure.

Method used

Through the structural modification of β-carbolin derivative JYJ-21, a series of β-carbolin derivatives with diverse structures were synthesized to optimize their in vitro anti-hepatocarcinoma activities, in order to develop new anti-hepatocarcinoma drugs, using Pictet-Spengler reaction, Synthesis routes such as Wittig reactions improve the preparation efficiency and activity of compounds.

Benefits of technology

It has obtained good inhibitory activity on liver cancer cells, especially the inhibitory activity on HepG2 cells is better than that on Hep3B cells. The preparation method has shortened reaction time, reduced cost, and improved reaction yield, providing potential anti-hepatocellular drug candidates.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN116535403B_ABST
    Figure CN116535403B_ABST
Patent Text Reader

Abstract

The present invention belongs to the field of pharmaceutical chemistry and organic compound synthesis technology, and specifically relates to a β-carboline derivative and its preparation method, a pharmaceutical composition and its use in the preparation of anti-liver cancer drugs. First, the β-carboline derivative has good inhibitory activity against liver cancer cells, wherein the inhibitory activity against HepG2 cells is better than that against Hep3B cells. Secondly, the preparation method of the β-carboline derivative of the present invention has the advantages of shortened reaction time, reduced experimental cost, and improved reaction yield. The structure of the β-carboline derivative of the present invention is shown in the general formula JYJ-a: #imgabs0#
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention belongs to the technical field of pharmaceutical chemistry and organic compound synthesis, and specifically relates to a beta-carboline derivative and a preparation method thereof, a pharmaceutical composition and application thereof in the preparation of an anti-liver cancer drug. Background Art

[0002] Primary liver cancer is one of the most common malignant tumors in my country and even in the world. Its incidence ranks fourth among tumors, and its mortality ranks fourth among tumors. Although some treatment methods, such as surgical resection, liver transplantation, chemotherapy and ablation, have achieved significant therapeutic effects, the 5-year survival rate of liver cancer patients is only 18%. Surgical resection is the main treatment for patients with early and middle-stage liver cancer, but because liver cancer has an insidious onset and rapid progression, it is mostly in the late stage when diagnosed. About 2 / 3 of patients have missed the best time for surgical treatment, and liver cancer is not sensitive to radiotherapy and chemotherapy. Therefore, targeted drug therapy has become a common treatment for patients with advanced liver cancer. However, for liver cancer patients, the number of targeted drugs currently available is limited, and the standard treatment regimen represented by sorafenib is not ideal. On average, it can only extend the survival time of liver cancer patients by about 2.8 months. The survival of liver cancer patients is not optimistic. Therefore, the development of drugs for the treatment of liver cancer is an important direction in the field of new drug research and development, especially the urgent need to develop anti-liver cancer drugs with a new mechanism of action and a new structure.

[0003] Harmaline can be considered as a pyridoindole alkaloid, among which β-harmaline is widely distributed in nature, including plants, fungi, marine organisms, animals, and even in human tissues and blood. Since Harmaline was first isolated from the seeds of Peganum harmala in 1841, researchers have conducted a lot of research on β-harmaline and found that β-harmaline alkaloids have good pharmacological activities, including anti-cancer, anti-bacterial, anti-anxiety, anti-fungal, anti-viral, anti-HIV, anti-Alzheimer's, anti-malarial and anticonvulsant activities. The β-harmaline derivative JYJ-21 extracted from the traditional Chinese medicine Quassus by the cooperative research group of the inventor in the early stage showed potential liver cancer cell toxicity, and its IC 50 The value is 3.21μM, which is better than the positive drug 5-fluorouracil (5-FU) and comparable to the first-line clinical drug sorafenib. However, the extraction of β-carboline derivatives JYJ-21 from the traditional Chinese medicine Quassus has the disadvantages of low yield and complex extraction and purification process. Summary of the invention

[0004] In order to solve the problems existing in the prior art, the present invention synthesized the natural product β-carboline derivative JYJ-21 for the first time. Secondly, the present invention uses the β-carboline skeleton as the lead compound, performs structural modification on it, designs and synthesizes a series of β-carboline derivatives with diverse structures, and preliminarily evaluates their in vitro anti-liver cancer activity, in order to obtain highly active new compounds, laying the foundation for the development and clinical application of new anti-liver cancer drugs.

[0005] Specifically, the present invention is realized through the following technical solutions:

[0006] In the first aspect, the present invention provides a β-carboline derivative represented by the general formula JYJ-a or a pharmaceutically acceptable salt thereof:

[0007]

[0008] Wherein, R1 is an alkenyl or alkynyl group containing 2-12 carbon atoms, or an alkoxycarbonyl alkenyl group containing 1-5 carbon atoms; R2 is hydrogen, or an alkyl or alkoxy group containing 1-5 carbon atoms; R3 is hydrogen, or an alkyl or alkoxy group containing 1-5 carbon atoms, or a halogen; R4 is hydrogen, or an alkyl group containing 1-5 carbon atoms, or an aralkyl group optionally substituted by an alkoxy group containing 1-5 carbon atoms, or an alkoxycarbonyl group containing 1-5 carbon atoms; R5 is hydrogen, or an alkoxy group containing 1-5 carbon atoms; wherein R2-R5 are not hydrogen at the same time, and the β-carboline derivative does not include compound JYJ-21 having the following structure:

[0009]

[0010] Preferably, R1 is an alkenyl or alkynyl group having 2-3 carbon atoms, or an alkoxycarbonylvinyl group having 1-3 carbon atoms.

[0011] More preferably, R1 is -CH=C(R6R7), -C≡CR6, or -CH=CHCO2R8, wherein R6-R8 are each independently selected from hydrogen or an alkyl group containing 1 to 5 carbon atoms.

[0012] Preferably, R2 is hydrogen, or an alkyl or alkoxy group containing 1 to 3 carbon atoms.

[0013] More preferably, R2 is hydrogen, or methyl, ethyl, methoxy, or ethoxy.

[0014] Preferably, R3 is hydrogen, or an alkyl or alkoxy group containing 1 to 3 carbon atoms, or a halogen.

[0015] More preferably, R3 is hydrogen, or methyl, ethyl, methoxy, ethoxy, or chlorine or bromine.

[0016] Preferably, R4 is hydrogen, or an alkyl group having 1 to 3 carbon atoms, or a phenylmethyl group optionally substituted by an alkoxy group having 1 to 3 carbon atoms, or an alkoxycarbonyl group having 1 to 4 carbon atoms.

[0017] More preferably, R4 is hydrogen, or methyl, ethyl, n-propyl, isopropyl, or phenylmethyl optionally substituted by a substituent selected from methoxy and ethoxy, or methoxycarbonyl, ethoxycarbonyl, isopropoxycarbonyl, or tert-butoxycarbonyl.

[0018] Preferably, R5 is hydrogen or an alkoxy group containing 1 to 3 carbon atoms.

[0019] More preferably, R5 is hydrogen.

[0020] Furthermore, the present invention preferably has the following structural formulas as shown in JYJ-1-JYJ-8:

[0021]

[0022] In the present invention, the term "halogen" means fluorine, chlorine, bromine or iodine.

[0023] In the present invention, the term "alkyl" (including when used alone and contained in other groups) means branched and straight-chain saturated hydrocarbon groups including 1-20 carbon atoms, preferably 1-12 carbon atoms, more preferably 1-5 carbon atoms, and most preferably 1-3 carbon atoms, such as methyl, ethyl, n-propyl, isopropyl, n-butyl, tert-butyl, isobutyl, pentyl, hexyl, heptyl, octyl, nonyl, decyl, 4,4-dimethylpentyl, 2,2,4-trimethylpentyl, undecyl, dodecyl, and various isomers thereof, etc.

[0024] In the present invention, the term "alkoxy" refers to an alkyl group with the stated number of carbon atoms connected via an oxygen bridge. Thus, "alkoxy" encompasses the above definition of alkyl.

[0025] In the present invention, the term "alkenyl" refers to a straight chain or branched hydrocarbon group containing a specified number of carbon atoms and at least one carbon-carbon double bond. Preferably, there is one carbon-carbon double bond, and more preferably, the carbon-carbon double bond is connected to the other parts of the compound. The number of carbon atoms can be 2-12, preferably 2-5, and more preferably 2, such as vinyl, 1-propenyl, 1-butenyl, etc.

[0026] In the present invention, the term "alkynyl" refers to a straight chain or branched hydrocarbon group containing a specified number of carbon atoms and at least one carbon-carbon triple bond. Preferably, there is a carbon-carbon triple bond, and more preferably, the other parts of the compound are connected through the carbon-carbon triple bond. The number of carbon atoms can be 2-12, preferably 2-5, and more preferably 2, such as ethynyl, 1-propynyl, 1-butynyl, etc.

[0027] In the present invention, the term "aralkyl" refers to an aryl-alkyl group, and the other parts of the compound are connected through the alkyl group. The "aryl" refers to an aromatic hydrocarbon group with 6-20 carbon atoms, preferably 6-14 carbon atoms, more preferably 6-10 carbon atoms, such as phenyl, naphthyl, etc. The alkyl group is defined as the above alkyl group. Therefore, the aralkyl group includes, for example, phenylmethyl, phenylethyl, etc.

[0028] In the second aspect, the present invention provides a method for preparing a β-carboline derivative represented by the general formula JYJ-a, wherein the method for preparing a β-carboline derivative in which R1 is an alkenyl group, R2 is a methoxy group, and R4 is hydrogen, comprises the following steps: using substituted tryptamine 4-a as a raw material, obtaining intermediate 5-a by Pictet-Spengler reaction, protecting intermediate 5-a by acetyl group at N-2 position, obtaining tetrahydro β-carboline intermediate 6-a, oxidizing intermediate 6-a to obtain intermediate 7-a, and then oxidative aromatizing to obtain intermediate 8-a, selectively reducing intermediate 8-a to aldehyde to obtain intermediate 9-a, and finally subjecting intermediate 9-a to Wittig reaction to synthesize target compound JYJ-a. The synthetic route is as follows:

[0029]

[0030] Among them, R3 is hydrogen, or an alkyl or alkoxy group containing 1-5 carbon atoms, or halogen; R5 is hydrogen, or an alkoxy group containing 1-5 carbon atoms; R6 is hydrogen, or an alkyl group containing 1-5 carbon atoms; R7 is hydrogen, or an alkyl group containing 1-5 carbon atoms.

[0031] Preferably, the method comprises the following steps: using substituted tryptamine 4-a as a raw material, obtaining intermediate 5-a through Pictet-Spengler reaction, protecting intermediate 5-a through N-2 acetyl group to obtain tetrahydro β-carboline intermediate 6-a, oxidizing intermediate 6-a through DDQ benzyl position to obtain intermediate 7-a, and then oxidizing aromatization under p-TsOH, 2,2-dimethoxypropane, tetrachlorobenzoquinone to obtain intermediate 8-a, selectively reducing intermediate 8-a to aldehyde through DIBAL-H to obtain intermediate 9-a, and finally subjecting intermediate 9-a to Wittig reaction to synthesize target compound JYJ-a. The synthetic route is as follows:

[0032] Among them, R3 is hydrogen, or an alkyl or alkoxy group containing 1-5 carbon atoms, or halogen; R5 is hydrogen, or an alkoxy group containing 1-5 carbon atoms; R6 is hydrogen, or an alkyl group containing 1-5 carbon atoms; R7 is hydrogen, or an alkyl group containing 1-5 carbon atoms.

[0033] In one embodiment, the preparation method of the β-carboline derivative JYJ-21 in which R1 is vinyl, R2 is methoxy, R3 is hydrogen, R4 is hydrogen, and R5 is methoxy comprises the following steps: using 7-methoxyindole as the starting material, introducing a formyl group at the electron-rich 3 position of indole by Vilsmeier-Haack reaction to obtain intermediate 2, then Henry reaction under the action of nitromethane to obtain unsaturated nitro intermediate 3, intermediate 3 is reduced by LiAlH4 to obtain 7-methoxytryptamine 4, then by Pictet-Spengler reaction and acetyl protection to obtain tetrahydro β-carboline intermediate 6, intermediate 6 is oxidized at the 4 position by DDQ to obtain intermediate 7, then oxidative aromatization is carried out under the conditions of p-TsOH, 2,2-dimethoxypropane, tetrachlorobenzoquinone to obtain intermediate 8, intermediate 8 is selectively reduced to aldehyde by DIBAL-H at -78°C, and finally intermediate 9 is subjected to Wittig reaction to obtain the target compound JYJ-21. The synthetic route is as follows:

[0034]

[0035] Among them, the preparation method of β-carboline derivatives in which R2 is hydrogen comprises the following steps: using substituted tryptamine 4-a as a raw material, obtaining a key intermediate through Pictet-Spengler reaction and oxidative aromatization, and then obtaining the target compound JYJ-a through a series of functional group transformations. The synthetic route is as follows:

[0036]

[0037] Among them, R1 is an alkynyl group containing 2-12 carbon atoms, or an alkoxycarbonylalkenyl group containing 1-5 carbon atoms; R3 is hydrogen, or an alkyl or alkoxy group containing 1-5 carbon atoms, or a halogen; R4 is hydrogen, or an alkyl group containing 1-5 carbon atoms, or an aralkyl group optionally substituted by an alkoxy group containing 1-5 carbon atoms, or an alkoxycarbonyl group containing 1-5 carbon atoms; R5 is hydrogen, or an alkoxy group containing 1-5 carbon atoms; and R3-R5 are not hydrogen at the same time.

[0038] Among them, the preparation method of the β-carboline derivative in which R1 is an alkenyl group, R2 is an alkyl group, and R4 is hydrogen comprises the following steps: using the substituted indole 12-a as a raw material, firstly acylating with DMF under the catalysis of phosphorus oxychloride to synthesize the substituted indole-3-carboxaldehyde 13-a, then reacting with nitromethane and Grignard reagent in sequence to obtain the intermediate 15-a, then reducing with Zn to synthesize the alkyl-substituted tryptamine 16-a, and then performing Pictet-Spengler reaction, oxidative aromatization, acetal deprotection and Wittig reaction to obtain the target compound JYJ-a; the synthesis route is as follows:

[0039]

[0040] Among them, R3 is hydrogen, or an alkyl or alkoxy group containing 1-5 carbon atoms, or halogen; R5 is hydrogen, or an alkoxy group containing 1-5 carbon atoms; R6 is hydrogen, or an alkyl group containing 1-5 carbon atoms; R7 is hydrogen, or an alkyl group containing 1-5 carbon atoms; R is an alkyl group containing 1-5 carbon atoms.

[0041] In a third aspect, the present invention provides a pharmaceutical composition comprising a β-carboline derivative represented by the general formula JYJ-a or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier or excipient.

[0042] In a fourth aspect, the present invention provides a use of a β-carboline derivative represented by the general formula JYJ-a or a pharmaceutically acceptable salt thereof or the pharmaceutical composition in the preparation of an anti-liver cancer drug.

[0043] The results of the in vitro anti-liver cancer cell activity test show that the β-carboline derivatives represented by the general formula JYJ-a of the present invention have good inhibitory activity against liver cancer cells, among which the inhibitory activity against HepG2 cells is better than that against Hep3B cells. In the general formula JYJ-a, when R1 is ethylene substituted, the anti-liver cancer activity is the best, which is better than the clinical first-line drug sorafenib, and is improved by one order of magnitude. When R2 is methyl substituted, the inhibitory activity against Hep3B cells is equivalent to that of unsubstituted, and greater than that of methoxy substituted; for compounds substituted with indole rings, the inhibitory activity against HepG2 cells is equivalent to that of unsubstituted, and the inhibitory activity against Hep3B cells is improved.

[0044] Compared with the prior art, the present invention has the following beneficial effects:

[0045] (1) The β-carboline derivatives of the present invention have good inhibitory activity against liver cancer cells, and their inhibitory activity against HepG2 cells is better than that against Hep3B cells. They have the potential to become anti-liver cancer drugs, enriching the diversity of such compounds.

[0046] (2) The method for preparing the β-carboline derivatives of the present invention has the advantages of shortening the reaction time, reducing the experimental cost, and improving the reaction yield. DETAILED DESCRIPTION

[0047] The embodiments of the present invention are described in detail below. The embodiments are given to better illustrate the contents of the present invention and are only used to explain the present invention, but should not be understood as limiting the present invention.

[0048] If no specific techniques or conditions are specified in the examples, the techniques or conditions described in the literature in the field or the product instructions are used. If no manufacturer is specified for the reagents or instruments used, they are all conventional products that can be purchased through regular channels.

[0049] The experimental methods in the following examples are conventional methods unless otherwise specified. The experimental materials used in the following examples are commercially available products unless otherwise specified.

[0050] Example 1: A method for preparing 4,8-dimethoxy-1-vinyl-9H-pyrido[3,4-b]indole (JYJ-21), wherein the steps are as follows:

[0051]

[0052] (1) Synthesis of intermediate (2)

[0053]

[0054] Anhydrous DMF (28.5 mL) was placed in a round-bottom flask, and phosphorus oxychloride (15.63 g, 0.1 mol) was added dropwise in an ice-water bath under nitrogen protection. After the reaction for 1 h, substituted indole (10.0 g, 68 mmol) was dissolved in anhydrous DMF (10 mL) and added to the reaction solution in an ice-water bath. After the addition, the ice-water bath was removed and the reaction was carried out at room temperature for 2 h. 2 mol / L sodium hydroxide solution (153 mL) was added in an ice-water bath, and the mixture was heated under reflux for 20 min. After the reaction was completed, the mixture was allowed to stand overnight to precipitate crystals, and the solid was filtered and washed with water to obtain a crude product. The filtrate was extracted with ethyl acetate (50 mL × 3), the organic phases were combined, and the mixture was washed with saturated brine for 3 times. The organic phases were combined, dried with anhydrous sodium sulfate, and the solvent was evaporated to dryness. After the product was obtained, it was combined with the solid obtained previously to obtain a crude product (2), which was directly subjected to the next step of reaction without purification.

[0055] (2) Synthesis of intermediate (3)

[0056]

[0057] The crude product (2) (6.83 g, 39 mmol) and ammonium acetate (8.98 g, 117 mmol) obtained above were placed in a dry round-bottom flask, nitromethane (116.5 mL) was added, and the mixture was heated to reflux for 1 h. The mixture was cooled to precipitate a solid, which was filtered and washed with water to obtain a crude product. The filtrate was extracted with ethyl acetate (50 mL × 3), the organic phases were combined, and the mixture was washed three times with saturated brine. The organic phases were combined, dried over anhydrous sodium sulfate, and the solvent was evaporated to dryness. After the product was obtained, it was combined with the crude product solid obtained previously to obtain a crude product (3), which was directly subjected to the next step of reaction without purification.

[0058] (3) Synthesis of intermediate (4)

[0059]

[0060] The crude product (3) (8.01 g, 36.7 mmol) was dissolved in anhydrous tetrahydrofuran (200 mL). Lithium aluminum tetrahydride (8.35 g, 220 mmol) was carefully added in several portions under an ice-water bath. After the addition was completed, the mixture was reacted at room temperature for 0.5 h. The reaction was monitored by TLC. After the reaction was completed, the mixture was placed under an ice-water bath and water (8.35 mL), 15% sodium hydroxide solution (8.35 mL), and water (16.7 mL) were carefully added dropwise in sequence to quench the reaction. The reaction solution was filtered through a Buchner funnel, and the reaction solution was washed with ethyl acetate. The filtrate was evaporated to dryness to obtain the crude product (4). A light yellow solid (4) was obtained by silica gel flash column chromatography (DCM / MeOH, 10:1).

[0061] (4) Synthesis of intermediate (6) ethyl 2-acetyl-8-methoxy-2,3,4,9-tetrahydro-1H-pyrido[3,4-b]indole-1-carboxylate

[0062]

[0063] Intermediate (4) (3.0 g, 15.8 mmol) was dissolved in methanol (30 mL) and added to a toluene (50% v / v) solution of ethyl glyoxylate (3.75 g, 18.9 mmol) at 0°C. After 10 min, the mixture was refluxed at 90°C for 1 h. The reaction was monitored for completion, the solvent was dried by rotary evaporation, saturated sodium bicarbonate solution was added to quench the reaction, the mixture was extracted with ethyl acetate, the mixture was washed with saturated brine 3 times, the organic phases were combined, anhydrous sodium sulfate was added to dry, and the solvent was evaporated under reduced pressure to obtain a crude product. No further purification was required. The crude product was dissolved in DCM with DMAP, triethylamine and acetyl chloride were added at 0°C under N2 protection, and the mixture was stirred at room temperature overnight. The reaction was monitored for completion, the solvent was dried by rotary evaporation under reduced pressure, saturated sodium bicarbonate solution was added to quench the reaction, the mixture was extracted with ethyl acetate, the mixture was washed with saturated brine 3 times, the organic phases were combined, anhydrous sodium sulfate was added to dry, and the solvent was evaporated under reduced pressure to obtain a crude product. The yellow solid intermediate (6) was obtained by silica gel flash column chromatography (ethyl acetate / petroleum ether, 1:1), Rf=0.2 (petroleum ether / ethyl acetate=1:1). 1H NMR (600MHz, CDCl3) δ8.48(s,1H),7.10(d,J=7.9Hz,1H),7.04(t,J=7.8Hz,1H),6.67(d,J=7.6Hz,1H),6.15(s,1H),4.31–4.2 1(m,2H),4.14(d,J=13.8Hz,1H),3.97(s,3H),3.69–3.58(m,1H),2.85(t,J=15.4Hz,2H),2.29(s,3H),1.32(t,J=7.1Hz,3H).

[0064] (5) Synthesis of intermediate (8)

[0065]

[0066] Intermediate (6) (1.5 g, 5.2 mmol) and DDQ (5.9 g, 26.2 mmol) were placed in an eggplant-shaped flask and stirred until uniformly distributed. A THF aqueous solution (THF–H2O=9:1 v / v; 35 mL) was slowly added dropwise at -78°C. After 1 h, the mixture was placed at 0°C and stirred at room temperature overnight. The reaction was monitored for completion, and the solvent was evaporated under reduced pressure. A saturated sodium bicarbonate solution was added to quench the reaction, and the mixture was extracted with dichloromethane and washed with saturated brine three times. The organic phases were combined, dried over anhydrous sodium sulfate, and the solvent was evaporated under reduced pressure to obtain a crude product. The crude product was directly carried out to the next step without further purification. The crude product, p-toluenesulfonic acid (1.2 g, 6.3 mmol), 2,2-dimethoxypropane (1.9 mL, 15.8 mmol) were stirred at room temperature for 30 min, and then tetrachlorobenzoquinone was added. The mixture was stirred at room temperature overnight. The reaction was monitored for completion, and the solvent was evaporated under reduced pressure. A saturated sodium bicarbonate solution was added to quench the reaction. The mixture was extracted with dichloromethane and washed with saturated brine three times. The organic phases were combined, dried over anhydrous sodium sulfate, and the solvent was evaporated under reduced pressure to obtain a crude product. The solid intermediate (8) was obtained by silica gel flash column chromatography (petroleum ether / ethyl acetate, 2:1).

[0067] (6) Synthesis of intermediate (9) 4,8-dimethoxy-9H-pyrido[3,4-b]indole-1-carbaldehyde

[0068]

[0069] Intermediate (8) (100 mg, 0.41 mmol) was dissolved in dichloromethane (30 mL), and DIBAL-H solution (1.5 M in toluene; 4.0 mL, 2.87 mmol) was slowly added dropwise at -78 °C. The mixture was stirred at -78 °C for 10 min. After monitoring the completion of the reaction, methanol (3.5 mL) and 10% NaOH (2.35 mmol) solution were slowly added dropwise to quench the reaction. The mixture was moved to room temperature and stirred for 1 h. The mixture was passed through a sand core funnel and washed three times with dichloromethane: methanol = 10:1, then combined and washed twice with saturated brine. The organic phases were combined, dried with anhydrous sodium sulfate, and the solvent was evaporated under reduced pressure to obtain a crude intermediate (9). Rf = 0.2 (petroleum ether / ethyl acetate = 4:1), 1 H NMR (400MHz, CDCl3) δ10.20(s,1H),10.11(s,1H),8.23(s,1H),7.86(d,J=7.9H z, 1H), 7.26 (d, J = 15.8Hz, 2H), 7.01 (d, J = 7.8Hz, 1H), 4.26 (s, 3H), 4.03 (s, 3H).

[0070] (7) Synthesis of the target compound 4,8-dimethoxy-1-vinyl-9H-pyrido[3,4-b]indole (JYJ-21)

[0071] CH3PPh3Br (765.2 mg, 2.04 mmol) was dissolved in anhydrous tetrahydrofuran, and n-BuLi (0.82 mL, 2.04 mmol, 2.5 M in hexane) was added at 0°C under N2 protection. After 10 minutes, the mixture was moved to room temperature for 2 hours. Then, the mixture was moved to 0°C, and the intermediate (9) (100 mg, 0.51 mmol) was dissolved in anhydrous tetrahydrofuran and slowly added by syringe. After 10 minutes, the mixture was allowed to react overnight at room temperature. The reaction was monitored until completion. The reaction was quenched with saturated NH4Cl at 0°C, extracted with dichloromethane, and washed with saturated brine three times. The organic phases were combined, dried with anhydrous sodium sulfate, and the solvent was evaporated under reduced pressure to obtain a crude product. The target product JYJ-21 was obtained as a yellow solid by silica gel flash column chromatography (petroleum ether / ethyl acetate, 2:1). The yield was 48%, and Rf=0.2 (petroleum ether / ethyl acetate=1:1). 1 H NMR (400MHz, CDCl3) δ8.55(s,1H),8.08(s,1H),7.90(d,J=7.9Hz,1H),7.25–7.11(m,2H),6.9 8(d,J=7.8Hz,1H), 6.23(d,J=17.5Hz,1H), 5.60(d,J=11.6Hz,1H), 4.16(s,3H), 4.03(s,3H).

[0072] Example 2: A method for preparing 9-ethyl-1-vinyl 9H-pyrido[3,4-b]indole (JYJ-1), wherein the steps are as follows:

[0073]

[0074] (1) Synthesis of intermediate (A) 1-dimethoxymethyl-9H-pyrido[3,4-b]indole

[0075]

[0076] Tryptamine (1.5 g, 9.36 mmol) was dissolved in dichloromethane (90 mL), and glyoxal dimethyl acetal (60% aqueous solution) (1.17 g, 11.23 mmol) and 5% trifluoroacetic acid were added, and stirred at 90 ° C for 1 h. After the reaction was completed, saturated sodium bicarbonate was added to quench the reaction, and the mixture was extracted with dichloromethane and washed with saturated brine for 3 times. The organic phases were combined, dried over anhydrous sodium sulfate, and the solvent was evaporated under reduced pressure to obtain a crude product.

[0077] The unseparated product obtained above was dissolved in anhydrous tetrahydrofuran, KMnO4 (4.44 g, 28.08 mmol) was added in batches, and the mixture was stirred at room temperature overnight. The reaction was monitored until the reaction was completed, and the mixture was filtered through a sand core funnel. The solvent was spin-dried under reduced pressure, and a gray oily acetal intermediate (A) was obtained by silica gel flash column chromatography (petroleum ether / ethyl acetate, 2:3) with a yield of 66%, Rf = 0.2 (petroleum ether / ethyl acetate = 2:1). 1 H NMR (600MHz, CDCl3) δ9.21 (s, 1H), 8.45 (d, J = 5.1Hz, 1H), 8.12 (t, J = 8.8Hz, 1H), 7.9 3(d,J=5.1Hz,1H),7.50–7.57(m,2H),7.28–7.25(m,1H),5.74(s,1H),3.51(s,6H); 13 C NMR (150MHz, CDCl3) δ140.37,140.33,138.31,133.60,130.15,128.65,121.70,121.16,119.97,114.98,111.65,106.63,54.28.

[0078] (2) Synthesis of intermediate (B) 9H-pyrido[3,4-b]indole-1-carboxaldehyde

[0079]

[0080] Intermediate (A) (1.48 g, 6.18 mmol) was dissolved in glacial acetic acid: 1,4-dioxane: water (2:1:0.5), reacted at 100°C for 1 h, monitored the reaction until the reaction was completed, added saturated sodium bicarbonate to quench the reaction, extracted with ethyl acetate, washed with saturated brine 3 times, combined the organic phases, added anhydrous sodium sulfate to dry, and evaporated the solvent under reduced pressure to obtain a crude product. Silica gel flash column chromatography (DCM / MeOH, 19:1) was used to obtain a yellow solid aldehyde intermediate (B) (0.667 g, 55%); Rf = 0.2 (petroleum ether / ethyl acetate = 4:1). 1H NMR (600MHz, CDCl3) δ10.34(s,1H),10.09(s,1H),8.63(d,J=4.9Hz,1H),8.15(d,J=5.2Hz,2H),7.65–7.55(m,2H),7.35(t,J=7.4Hz,1H); 13 C NMR (150MHz, CDCl3) δ195.86,141.35,139.72,136.06,135.34,131.71,129.70,122.07,121.27,120.57,119.46,112.19.

[0081] (3) Synthesis of intermediate (C) 1-vinyl-9H-pyrido[3,4-b]indole

[0082]

[0083] CH3PPh3Br (765.2 mg, 2.04 mmol) was dissolved in anhydrous tetrahydrofuran, and n-BuLi (0.82 mL, 2.04 mmol, 2.5 M in hexane) was added at 0°C under N2 protection. After 10 minutes, the mixture was moved to room temperature for 2 hours. Then, the mixture was transferred to 0°C, and the intermediate (B) (100 mg, 0.51 mmol) was dissolved in anhydrous tetrahydrofuran and slowly added by syringe. After 10 minutes, the mixture was reacted at room temperature overnight. The reaction was monitored until completion. The reaction was quenched with saturated NH4Cl at 0°C, extracted with dichloromethane, washed with saturated brine 3 times, the organic phases were combined, dried with anhydrous sodium sulfate, and the solvent was evaporated under reduced pressure to obtain a crude product. The yellow solid intermediate (C) was obtained by silica gel flash column chromatography (petroleum ether / ethyl acetate, 2:1) with a yield of 45%, Rf=0.2 (petroleum ether / ethyl acetate=2:1). 1H NMR (600MHz, CDCl3) δ9.18(s,1H),8.49(d,J=5.2Hz,1H),8.13(d,J=7.9Hz,1H),7.89(d,J=5.2Hz,1H),7.59 –7.47(m,2H),7.30(t,J=7.0Hz,1H),7.26(t,J=5.5Hz,1H),6.42(d,J=18.2Hz,1H),5.66(d,J=11.7Hz,1H); 13 C NMR (150MHz, CDCl3) δ140.62,139.97,139.15,133.86,133.00,130.11,128.67,121.87,121.85,120.36,119.29,114.26,111.77.

[0084] (4) Synthesis of the target compound 9-ethyl-1-vinyl 9H-pyrido[3,4-b]indole (JYJ-1)

[0085] Intermediate (C) (100 mg, 0.51 mmol) was dissolved in DMF, cesium carbonate (302 mg, 0.93 mmol) was added, and after stirring at room temperature for 10 min, iodoethane (96.36 mg, 0.62 mmol) was slowly added, and the reaction was allowed to react at room temperature for 2 h. The reaction was monitored until the reaction was completed, the solvent was dried, saturated ammonium chloride solution was added to quench the reaction, and the mixture was extracted with ethyl acetate and washed with saturated brine three times. The organic phases were combined, dried over anhydrous sodium sulfate, and the solvent was evaporated under reduced pressure to obtain a crude product. The yellow solid JYJ-1 was obtained by silica gel flash column chromatography (petroleum ether / ethyl acetate, 6:1) with a yield of 85%, Rf=0.2 (petroleum ether / ethyl acetate=3:1). 1 H NMR (600MHz, CDCl3) δ8.45(d,J=5.1Hz,1H),8.11(d,J=7.8Hz,1H),7.88(d,J=5.1Hz,1H),7.60–7.56(m,1H),7.52–7.48(m,1H),7.47–7.4 3(m,1H),7.26(d,J=7.1Hz,1H),6.40(dd,J=16.8,1.9Hz,1H),5.66(dd,J=10.7,1.9Hz,1H),4.56(q,J=7.2Hz,2H),1.49(t,J=7.2Hz,3H); 13C NMR (150MHz, CDCl3) δ141.51,140.04,138.56,133.72,133.03,130.31,128.43,12 1.54,121.24,120.44,119.77,113.96,109.42,77.28,77.07,76.85,40.07,15.18.

[0086] Example 3: A method for preparing 9-(4-methoxybenzyl)-1-vinyl-9H-pyrido[3,4-b]indole (JYJ-2), wherein the steps are as follows:

[0087]

[0088] Referring to the synthesis method of JYJ-1, PMBBr was used instead of iodoethane in the steps to obtain the target product JYJ-2 as a yellow solid with a yield of 83%; Rf = 0.2 (petroleum ether / ethyl acetate = 4:1). 1 HNMR(600MHz, CDCl3) δ8.48(d,J=5.1Hz,1H),8.16(d,J=7.8Hz,1H),7.93(d,J= 5.1Hz,1H),7.54(t,J=7.7Hz,1H),7.36(d,J=8.3Hz,1H),7.31(t,J=7.5Hz,1H) ,7.27(d,J=10.8Hz,1H),7.24(s,1H),7.04(d,J=8.6Hz,2H),6.84(d,J=8.7Hz, 2H),6.32(d,J=15.1Hz,1H),5.69(s,2H),5.49(d,J=12.4Hz,1H),3.77(s,3H); 13 C NMR(150MHz,DMSO)δ159.20,142.51,140.57,139.22,134.69,133.25,130.48,129.47,1 28.82,126.98,121.66,121.47,120.40,120.33,114.61,114.08,110.08,55.42,48.64.

[0089] Example 4: Preparation of 1-vinyl-9H-pyrido[3,4-b]indole-9-tert-butyloxycarbonyl (JYJ-3), the steps are as follows:

[0090]

[0091] Intermediate (C) (100 mg, 0.51 mmol), Boc2O (224.7 mg, 1.03 mmol), TEA (0.86 mg, 0.77 mmol) were dissolved in anhydrous dichloromethane, DMAP (12.58 mg, 0.1 mmol) was added at 0°C, and the mixture was moved to room temperature for 2 h after 20 min. The reaction was monitored until the reaction was completed, the solvent was dried, extracted with ethyl acetate, washed with saturated brine 3 times, the organic phases were combined, dried over anhydrous sodium sulfate, and the solvent was evaporated under reduced pressure to obtain a crude product, which was purified by silica gel flash column chromatography (petroleum ether / ethyl acetate = 4:1) to obtain a white solid JYJ-3, Rf = 0.2 (petroleum ether / ethyl acetate = 4:1). 1 H NMR (600MHz, CDCl3) δ8.59(d,J=4.9Hz,1H),8.19(d,J=8.4Hz,1H),8.01(d,J=7.7Hz,1H),7.76(d,J=4.9Hz,1H),7.59(t,J=7 .8Hz,1H),7.40(t,J=7.5Hz,1H),7.16(dd,J=17.0,10.7Hz,1H),6.46(d,J=17.0Hz,1H),5.56(d,J=10.7Hz,1H),1.69(s,9H); 13 C NMR (150MHz, CDCl3) δ148.28,141.46,140.69,138.39,132.56,131.91,130.48,127.26 ,122.37,121.14,118.61,115.07,113.53,110.40,82.75,74.85,74.64,74.42,25.74.

[0092] Example 5: A method for preparing 6-chloro-1-vinyl-9H-pyrido[3,4-b]indole (JYJ-4), wherein the steps are as follows:

[0093]

[0094] Referring to the synthesis method of intermediate (C), 5-chlorotryptamine was used instead of tryptamine in the steps to obtain the target product JYJ-4 as a yellow solid with a yield of 43% and Rf=0.2 (petroleum ether / ethyl acetate=3:1). 1HNMR (600MHz, CDCl3) δ8.57(s,1H),8.48(d,J=5.2Hz,1H),8.08(s,1H),7.83(d,J=5.2Hz,1H),7.51(d,J=10.6 Hz,1H),7.46(d,J=8.6Hz,1H),7.19(dd,J=17.4,11.1Hz,1H),6.40(d,J=18.0Hz,1H),5.72(d,J=11.6Hz,1H); 13 C NMR (150MHz, CDCl3) δ140.20,139.53,138.47,133.97,132.74,129.02,128 .79,125.92,122.97,121.44,119.56,114.06,112.65,77.23,77.02,76.81.

[0095] Example 6: A method for preparing 6-methoxy-1-vinyl-9H-pyrido[3,4-b]indole (JYJ-5), wherein the steps are as follows:

[0096]

[0097] Referring to the synthesis method of intermediate (C), 5-methoxytryptamine was used instead of tryptamine in the steps to obtain the target product JYJ-5 as a yellow solid with a yield of 43% and Rf=0.2 (petroleum ether / ethyl acetate=3:1). 1 HNMR (600MHz, CDCl3) δ8.92(s,1H),8.44(d,J=5.2Hz,1H),7.83(d,J=5.2Hz,1H),7.55(s,1H),7.41(d,J= 8.8Hz,1H),7.25–7.20(m,1H),7.19(s,1H),6.40(d,J=17.4Hz,1H),5.65(d,J=11.1Hz,1H),3.93(s,3H); 13 C NMR (150MHz, CDCl3) δ154.47,140.07,138.59,135.52,134.48,133.02,129.98,122.20,119.28,118.73,114.13,112.65,103.61,56.13.

[0098] Example 7: A method for preparing 6-methyl-1-vinyl-9H-pyrido[3,4-b]indole (JYJ-6), wherein the steps are as follows:

[0099]

[0100] Referring to the synthesis method of intermediate (C), 5-methyltryptamine was used instead of tryptamine in the steps to obtain the target product JYJ-6 as a yellow solid with a yield of 43% and Rf=0.2 (petroleum ether / ethyl acetate=3:1). 1 HNMR (600MHz, CDCl3) δ8.74(s,1H),8.45(d,J=4.9Hz,1H),7.91(s,1H),7.84(d,J=5.0Hz,1H),7.40(d,J=8.3Hz,1H) ,7.37(d,J=8.2Hz,1H),7.21(dd,J=17.4,11.1Hz,1H),6.39(d,J=17.5Hz,1H),5.67(d,J=11.1Hz,1H),2.54(s,3H); 13 C NMR (150MHz, CDCl3) δ139.85,139.00,138.79,134.07,133.14,130.20,129.94,129.90,122.03,121.58,119.15,114.16,111.40,21.52.

[0101] Example 8: A method for preparing 4-methyl-1-vinyl-9H-pyrido[3,4-b]indole (JYJ-7), wherein the steps are as follows:

[0102]

[0103] Referring to the synthesis method of intermediate (C), 2-(1H-indol-3-yl)propane-1-amine was used instead of tryptamine in the step to obtain the target product JYJ-7 as a white solid with a yield of 43% and Rf=0.2 (petroleum ether / ethyl acetate=3:1). 1 HNMR(600MHz, CDCl3)δ9.25(s,1H),8.24(s,1H),8.19(d,J=7.9Hz,1H),7.58–7.47(m,2H),7.31(t,J=7 .2Hz,1H),7.21(dd,J=17.5,11.1Hz,1H),6.35(d,J=17.5Hz,1H),5.60(d,J=11.1Hz,1H),2.81(s,3H); 13 C NMR (150MHz, CDCl3) δ140.44,139.55,137.67,133.28,132.76,128.59,127.85 ,126.83,123.55,122.36,120.23,118.24,111.53,77.25,77.04,76.83,17.46.

[0104] Example 9: A method for preparing 4,6-dimethoxy-1-vinyl-9H-pyrido[3,4-b]indole (JYJ-8), wherein the steps are as follows:

[0105]

[0106] Referring to the synthesis method of JYJ-21, the compound 5-methoxytryptamine was substituted for 7-methoxytryptamine in the steps to obtain the target product JYJ-8 as a yellow solid with a yield of 48%; Rf = 0.2 (petroleum ether / ethyl acetate = 1:1). 1 H NMR (600MHz, CDCl3) δ8.69(s,1H),8.06(s,1H),7.79(d,J=2.5Hz,1H),7.39(d,J=8.8Hz,1H),7.11– 7.17(m,2H),6.20(dd,J=17.6,1.0Hz,1H),5.56(dd,J=11.2,1.0Hz,1H),4.16(s,3H),3.94(s,3H); 13 C NMR (150MHz, CDCl3) δ154.52,151.44,135.40,134.48,134.21,133.19,121.73,121.19,118.74,117.53,116.88,111.97,106.16,56.28,56.18.

[0107] Example 10: Pharmacological Activity Experimental Section

[0108] (1) Instruments and Materials

[0109] Instruments: carbon dioxide incubator (Thermo, USA); 96-well culture plate (Nest Biotech, USA); Varioskan Flash multifunctional microplate reader (Thermo, USA), etc.

[0110] Reagents: Trypsin (Biological Industries, USA); fetal bovine serum (Biological Industries, USA); DMEM medium (HyClon, USA); MTT (Sigma, USA); Sorafenib (solarbio, Beijing, China), etc.

[0111] (2) Experimental cell lines

[0112] Human hepatoma cell lines HepG2 and Hep3B were purchased from American Type Culture Collection (ATCC, Rockville, MD, USA). The cells were inoculated in DMEM culture medium containing 10% fetal bovine serum, 10 μg / mL streptomycin and 100 U / mL penicillin and cultured in a 37°C, 5% CO2 incubator.

[0113] (3) Experimental methods

[0114] MTT method: Take tumor cells in the logarithmic growth phase, digest them with trypsin, and inoculate them in a 96-well culture plate at a density of 5000 cells per well. After culturing in the incubator for 12 hours, add 100 mL of drugs of different concentrations to each well, and add an equal volume of blank culture medium to the control group. Each group has 3 replicate wells, and the wells without cells are used as the background. After culturing at 37°C and 5% CO2 for 48 hours, add 20 mL / well of MTT, continue culturing for 4 hours, carefully discard the supernatant in the well, add 150 mL of DMSO to each well, and shake at room temperature to fully dissolve the crystals. Use an enzyme marker to detect the absorbance value at 492 nm, and repeat the experiment 3 times. The growth inhibition rate (%) = [A492 (negative control) - A492 (drug group)] / A492 (negative control) × 100%, and then use Graphpad data analysis software to calculate the half inhibitory concentration (IC 50 value).

[0115] (4) In vitro anti-hepatocellular carcinoma activity study

[0116] The MTT method was used to test the cytotoxic activity of some of the synthesized compounds against two liver cancer cells, HepG2 and Hep3B, using sorafenib as the standard. The results are shown in Table 1:

[0117] Table 1 Cytotoxicity of compounds to HepG2 and Hep3B cells (IC 50 ,μM)

[0118]

[0119] Note: a Positive control.

[0120] The results of the in vitro anti-liver cancer cell activity test show that the β-carboline derivatives represented by the general formula JYJ-a of the present invention have good inhibitory activity against liver cancer cells, among which the inhibitory activity against HepG2 cells is better than that against Hep3B cells. In the general formula JYJ-a, when R1 is ethylene substituted, the anti-liver cancer activity is the best, which is better than the clinical first-line drug sorafenib, and is improved by one order of magnitude. When R2 is methyl substituted, the inhibitory activity against Hep3B cells is equivalent to that of unsubstituted, and greater than that of methoxy substituted; for compounds substituted with indole rings, the inhibitory activity against HepG2 cells is equivalent to that of unsubstituted, and the inhibitory activity against Hep3B cells is improved.

[0121] Obviously, the above embodiments are only examples for clearly explaining the present invention, and are not intended to limit the implementation methods of the present invention. Those skilled in the art may make various changes and modifications to the present invention without departing from the spirit and scope of the present invention. Thus, if these modifications and variations of the present invention fall within the scope of the claims of the present invention and their equivalents, the present invention is also intended to include these modifications and variations.

Claims

1. A β-carboline derivative represented by the general formula JYJ-a or a pharmaceutically acceptable salt thereof, characterized in that: ; Wherein, R1 is -CH=C(R6R7), wherein R6 and R7 are selected from hydrogen; R2 is hydrogen or methyl; R3 is hydrogen, or methyl, methoxy, or chlorine; R4 is hydrogen; R5 is hydrogen, wherein R2-R5 are not hydrogen at the same time.

2. The β-carboline derivative represented by the general formula JYJ-a or a pharmaceutically acceptable salt thereof according to claim 1, characterized in that: The structural formula of the β-carboline derivative is shown in JYJ-4-JYJ-7: 。 3. A pharmaceutical composition, characterized in that The invention comprises the β-carboline derivative or a pharmaceutically acceptable salt thereof according to claim 1 or claim 2 and a pharmaceutically acceptable carrier.

4. Use of the β-carboline derivative or the pharmaceutically acceptable salt thereof according to claim 1 or claim 2 or the pharmaceutical composition according to claim 3 in the preparation of an anti-liver cancer drug.